Nuvectis Pharma, Inc.
NVCTNasdaqCIK 1875558HealthcareFiscal year ends Dec 31
Reports and events: 70 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-2116:31 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-099712 |
| 2026-08-0409:01 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-090109 |
| 2026-08-0408:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-090094 |
| 2026-06-3016:43 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-079360 |
| 2026-06-2916:07 ET | 8-K | 8.01 Other events | 0001104659-26-078823 |
| 2026-06-2307:00 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076624 |
| 2026-06-1216:05 ET | 8-K | 5.07 Shareholder vote results | 0001104659-26-073419 |
| 2026-05-0509:03 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-055318 |
| 2026-05-0507:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055264 |
| 2026-04-2716:37 ET | DEF 14A | Proxy statementPeriod 2026-06-11 | 0001104659-26-049476 |
| 2026-02-1108:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-013049 |
| 2026-02-1108:02 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-013044 |
| 2025-11-0408:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-105953 |
| 2025-11-0408:01 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-105939 |
| 2025-09-2508:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-25-093144 |
| 2025-08-0509:30 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-010203 |
| 2025-08-0508:39 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-073967 |
| 2025-06-1317:00 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-059435 |
| 2025-05-0917:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-046845 |
| 2025-05-0616:12 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-006497 |
| 2025-05-0608:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-044838 |
| 2025-04-2816:20 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001104659-25-040225 |
| 2025-02-2516:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-001496 |
| 2025-02-2509:26 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-016779 |
| 2025-02-0621:51 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-009813 |
| 2024-11-0508:31 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-014340 |
| 2024-11-0507:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-114097 |
| 2024-08-2908:52 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-094609 |
| 2024-08-0609:20 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-010971 |
| 2024-08-0608:51 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-086127 |
| 2024-06-1316:09 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-071261 |
| 2024-05-0716:30 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-007072 |
| 2024-05-0709:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-057782 |
| 2024-04-2916:30 ET | DEF 14A | Proxy statementPeriod 2024-06-13 | 0001104659-24-054082 |
| 2024-03-0517:20 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-002497 |
| 2024-03-0508:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-030773 |
| 2023-11-0808:39 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-115538 |
| 2023-11-0807:45 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-018124 |
| 2023-09-1208:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-099872 |
| 2023-08-1709:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-092871 |
| 2023-08-0916:29 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-089330 |
| 2023-08-0916:15 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-014266 |
| 2023-07-0308:00 ET | 8-K | 2.02 Results of operations | 0001104659-23-077410 |
| 2023-06-1616:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-23-072304 |
| 2023-05-1508:22 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-060239 |
| 2023-05-1016:30 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001558370-23-009133 |
| 2023-05-1009:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-058085 |
| 2023-04-2816:05 ET | DEF 14A | Proxy statementPeriod 2023-06-16 | 0001104659-23-052907 |
| 2023-03-2708:31 ET | 10-K/A | Annual report, amendedPeriod 2022-12-31 | 0001104659-23-036896 |
| 2023-03-0817:31 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001558370-23-003181 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.